Longevity Technology(@LongevityTech):GLP-1 receptor agonists and BPC-157 may share the peptide conversation, but their evidence is far from equal. Before believing the hype, ask what was actually studied, in whom, and for how long. Which peptide claim should we examine next? #longevity #geroscience #peptides

Longevity Technology

@LongevityTech

Daily news and insights on research, investments and technologies that extend life and improve the quality of that extended life. #Longevity#

加入 December 2018

2.3K 正在关注 19K 粉丝

Longevity Technology@LongevityTech

2026.10.14 12:27

GLP-1 receptor agonists and BPC-157 may share the peptide conversation, but their evidence is far from equal. Before believing the hype, ask what was actually studied, in whom, and for how long. Which peptide claim should we examine next? #longevity# #geroscience# #peptides#

显示更多